Standard Biotools (LAB) Cash & Equivalents Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn | 40.99% |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn | 21.52% |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn | -0.70% |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - | 16.75% |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | 30.29% |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn | 32.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.42% |
| Dec 31, 2025 | 13.66% |
| Sep 30, 2025 | 28.34% |
| Jun 30, 2025 | 28.15% |
| Mar 31, 2025 | 70.44% |
| Dec 31, 2024 | 78.93% |
| Sep 30, 2024 | 91.19% |
| Jun 30, 2024 | 543.79% |
| Mar 31, 2024 | 78.43% |
| Dec 31, 2023 | -8.94% |
| Sep 30, 2023 | 3.12% |
| Jun 30, 2023 | 48.11% |
| Mar 31, 2023 | 46.95% |
| Dec 31, 2022 | 51.37% |
| Sep 30, 2022 | 29.85% |
| Jun 30, 2022 | 42.37% |
| Mar 31, 2022 | -22.12% |
| Dec 31, 2021 | -32.40% |
| Sep 30, 2021 | -5.41% |
| Jun 30, 2021 | -70.46% |